NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: KREBSBIO · data 2026-10-30
Krebs Biochemicals & Industries Ltd.
In plain words
Price: 26.4% below its 52-week high of ₹76.85.
Delivery: 56.8% of traded shares were kept for delivery over the last 10 sessions, against 67.1% over the last 60.
Latest results: a net loss of ₹5 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹27 cr |
| Net profit (last 12 months) | ₹-13 cr |
| Sales growth, 3 years (yearly) | -23.3% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q2 FY27)
KREBSBIO Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹5.79 crore, up 38.8% YoY and down 17% QoQ.
Net loss was ₹5.4 crore, a smaller loss than a year ago and a bigger loss than last quarter.
Operating margin was 33.3% (67% a year ago).
EPS was -₹2.5, less negative than a year ago and more negative than last quarter.
KREBSBIO के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹5.79 करोड़; पिछले साल की तुलना में 38.8% की बढ़त, पिछली तिमाही की तुलना में 17% की गिरावट।
शुद्ध घाटा: ₹5.4 करोड़; एक साल पहले से घाटा कम हुआ, पिछली तिमाही से घाटा बढ़ा।
ऑपरेटिंग मार्जिन: 33.3% (एक साल पहले 67%)।
EPS: -₹2.5; एक साल पहले से कम ऋणात्मक, पिछली तिमाही से अधिक ऋणात्मक।
KREBSBIOના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹5.79 કરોડ; ગયા વર્ષની સરખામણીએ 38.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 17% ઘટાડો.
ચોખ્ખી ખોટ: ₹5.4 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ ઘટી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ વધી.
ઓપરેટિંગ માર્જિન: 33.3% (એક વર્ષ પહેલાં 67%).
EPS: -₹2.5; એક વર્ષ પહેલાંના કરતાં ઓછી નકારાત્મક, ગયા ક્વાર્ટરના કરતાં વધુ નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 16/30: Delivery 50.7% over the last 20 sessions vs 50.5% in the 40 before (1x); shares delivered per day 4.74x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹0.8 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Deal
- 29 Oct 26Results Q2 FY27 results: loss narrowed vs a year ago -4.3% next session
- 1 Oct 26Deal Bulk deal: VAIBHAV UPADHYAY sold ₹0.8 cr +6.2% next session
- 6 Aug 26Results Q1 FY27 results: loss narrowed vs a year ago +1.7% next session
- 21 May 26Results Q4 FY26 results: loss narrowed vs a year ago +6.7% next session
- 9 Feb 26Results Q3 FY26 results: loss narrowed vs a year ago -0.7% next session
- 4 Nov 25Results Q2 FY26 results: loss widened vs a year ago -1.8% next session
- 7 Aug 25Results Q1 FY26 results: loss widened vs a year ago -3.0% next session
- 20 May 25Results Q4 FY25 results: loss widened vs a year ago -2.4% next session
- 7 Mar 25Results Q3 FY25 results: loss widened vs a year ago -2.6% next session
- 11 Nov 24Results Q2 FY25 results: loss widened vs a year ago -6.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹6 cr | ₹-5 cr | — | -33.3% | -2.5 |
| Jun 2026 | ₹7 cr | ₹-2 cr | — | 11.8% | -1.15 |
| Mar 2026 | ₹7 cr | ₹-2 cr | — | -12.7% | -1.09 |
| Dec 2025 | ₹7 cr | ₹-3 cr | — | 4.1% | -1.45 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 72.74% | 72.74% | 72.74% | 72.74% |
| Foreign institutions (FII) | 0.50% | 0.50% | 0.50% | 0.50% |
| Domestic institutions (DII) | — | — | — | — |
| Mutual funds | — | — | — | — |
| Retail investors | 10.75% | 10.52% | 10.64% | 11.23% |
| Number of shareholders | 8,533 | 8,521 | 8,553 | 8,710 |
Common questions
What was Krebs Biochemicals & Industries Ltd.'s latest quarterly profit?
Krebs Biochemicals & Industries Ltd. reported a net loss of ₹5 cr for the quarter ended Sept 2026, on revenue of ₹6 cr.
How much do promoters hold in Krebs Biochemicals & Industries Ltd.?
Promoters held 72.74% of Krebs Biochemicals & Industries Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
What is the 52-week high and low of Krebs Biochemicals & Industries Ltd.?
The 52-week high is ₹76.85 and the 52-week low is ₹38.33.
Similar companies
Quest Laboratories Ltd. (QUESTLAB) · Bal Pharma Limited (BALPHARMA) · Parnax Lab Limited (PARNAXLAB) · Sotac Pharmaceuticals Limited (SOTAC) · Makers Laboratories Ltd (MAKERSL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KREBSBIO in NSE Scanner →